Literature DB >> 10903770

Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors.

P S Penglis1, L G Cleland, M Demasi, G E Caughey, M J James.   

Abstract

There is an autocrine relationship between eicosanoid and cytokine synthesis, with the ratio of prostaglandin E2 (PGE2)/thromboxane A2 (TXA2) being one of the determinants of the level of cytokine synthesis. In monocytes, cyclooxygenase type 1 (COX-1) activity appears to favor TXA2 production and COX-2 activity appears to favor PGE2 production. This has led to speculation regarding possible linkage of COX isozymes with PGE and TXA synthase. We have studied the kinetics of PGE2 and TXA2 synthesis under conditions that rely on COX-1 or -2 activity. With small amounts of endogenously generated prostaglandin H2 (PGH2), TXA2 synthesis was greater than PGE2. With greater amounts of endogenously generated PGH2, PGE2 synthesis was greater than TXA2. Also, TXA synthase was saturated at lower substrate concentrations than PGE synthase. This pattern was observed irrespective of whether PGH2 was produced by COX-1 or COX-2 or whether it was added directly. Furthermore, the inhibition of eicosanoid production by the action of nonsteroidal anti-inflammatory drugs or by the prevention of COX-2 induction with the p38 mitogen-activated protein kinase inhibitor SKF86002 was greater for PGE2 than for TXA2. It is proposed that different kinetics of PGE synthase and TXA synthase account for the patterns of production of these eicosanoids in monocytes under a variety of experimental conditions. These properties provide an alternative explanation to notional linkage or compartmentalization of COX-1 or -2 with the respective terminal synthases and that therapeutically induced changes in eicosanoid ratios toward predominance of TXA2 may have unwanted effects in long-term anti-inflammatory and anti-arthritic therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903770     DOI: 10.4049/jimmunol.165.3.1605

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes.

Authors:  S L Tilley; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Flurbiprofen axetil increases arterial oxygen partial pressure by decreasing intrapulmonary shunt in patients undergoing one-lung ventilation.

Authors:  Xiao-Qing Chai; Jun Ma; Yan-Hu Xie; Di Wang; Kun-Zhou Chen
Journal:  J Anesth       Date:  2015-08-14       Impact factor: 2.078

3.  Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.

Authors:  Patricia McGettigan; Pearline Han; David Henry
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 4.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype.

Authors:  Paul C Norris; Donna Reichart; Darren S Dumlao; Christopher K Glass; Edward A Dennis
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

6.  Thromboxane receptor signaling is required for fibronectin-induced matrix metalloproteinase 9 production by human and murine macrophages and is attenuated by the Arhgef1 molecule.

Authors:  John M Hartney; Claire E Gustafson; Russell P Bowler; Roberta Pelanda; Raul M Torres
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

7.  Long-term use of aspirin and the risk of gastrointestinal bleeding.

Authors:  Edward S Huang; Lisa L Strate; Wendy W Ho; Salina S Lee; Andrew T Chan
Journal:  Am J Med       Date:  2011-05       Impact factor: 4.965

8.  Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.

Authors:  Thomas J Montine; Joshua A Sonnen; Ginger Milne; Laura D Baker; John C S Breitner
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

9.  Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II.

Authors:  Zhonghua Qi; Chuan-Ming Hao; Robert I Langenbach; Richard M Breyer; Reyadh Redha; Jason D Morrow; Matthew D Breyer
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.

Authors:  Maung-Maung Thwin; Eleni Douni; Pachiappan Arjunan; George Kollias; Prem V Kumar; Ponnampalam Gopalakrishnakone
Journal:  Arthritis Res Ther       Date:  2009-09-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.